The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

This study is testing whether adding memantine (a drug normally used for Alzheimer's disease that may also protect liver function) to the standard combination of atezolizumab (immunotherapy) and bevacizumab (a drug that starves tumors of their blood supply) improves outcomes for people with advanced liver cancer that cannot be surgically removed. **You may be eligible if...** - You are 18 years or older - You have been newly diagnosed with hepatocellular carcinoma (the most common type of primary liver cancer) confirmed by tissue or imaging - Your cancer is locally advanced and cannot be surgically removed - You have not received prior treatment for liver cancer - You have reasonably preserved liver function (Child-Pugh score A5 or A6) - Your performance status is good (ECOG 0-1) and organ function meets required minimums **You may NOT be eligible if...** - You have previously received treatment for liver cancer - Your liver function is significantly impaired (Child-Pugh B or C) - You have a prior liver cancer that was treated, unless it was more than 2 years ago and your current cancer is a new occurrence - You have an active autoimmune condition or other major health problems that could interfere with the treatment Talk to your doctor to see if this trial is right for you.